[1]PITTOCK S J,LUCCHINETTI C F.Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies:a decade later[J].Ann N Y Acad Sci,2016,1366(1):20-39.DOI:10.1111/nyas.12794.
[2]WINGERCHUK D M,BANWELL B,BENNETT J L,et al.International consensus diagnostic criteria for neuromyelitis optica spectrum disorders[J].Neurology,2015,85(2):177-189.DOI:10.1212/WNL.0000000000001729.
[3]中国免疫学会神经免疫学分会,中华医学会神经病学分会神经免疫学组,中国医师协会神经内科分会神经免疫专业委员会.中国视神经脊髓炎谱系疾病诊断与治疗指南[J].中国神经免疫学和神经病学杂志,2016,23(3):155-166.
[4]WEINSHENKER B G,BARRON G,BEHNE J M,et al.Challenges and opportunities in designing clinical trials for neuromyelitis optica[J].Neurology,2015,84(17):1805-1815.DOI:10.1212/WNL.0000000000001520.
[5]LIU Y O,WANG J H,DAAMS M,et al.Differential patterns of spinal cord and brain atrophy in NMO and MS[J].Neurology,2015,84(14):1465-1472.DOI:10.1212/WNL.0000000000001441.
[6]STüVE O,WARNKE C,DEASON K,et al.CD19 as a molecular target in CNS autoimmunity[J].Acta Neuropathol,2014,128(2):177-190.DOI:10.1007/s00401-014-1313-z.
[7]VARRIN-DOYER M,SPENCER C M,SCHULZE-TOPPHOFF U,et al.Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter[J].Ann Neurol,2012,72(1):53-64.DOI:10.1002/ana.23651.
[8]VAKNIN-DEMBINSKY A,BRILL L,KASSIS I,et al.T-cell reactivity against AQP4 in neuromyelitis optica[J].Neurology,2012,79(9):945-946.DOI:10.1212/WNL.0b013e318266fc2b.
[9]CHIHARA N,ARANAMI T,SATO W,et al.Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica[J].Proc Natl Acad Sci USA,2011,108(9):3701-3706.DOI:10.1073/pnas.1017385108.
[10]CHANG-HUA C,SHAO-HUNG W,HUA-CHENG Y,et al.Successful treatment of meningoencephalitis due to Cryptococcus gattii with ommaya reservoir and intrathecal injection of amphotericin B-a case report[J].Cesk Slov Neurol N,2017,80/113(3):337-342.DOI:10.14735/amcsnn2017337.
[11]ROMMER P S,KAMIN F,ABU-MUGHEISIB M,et al.Long-term effects of repeated cycles of intrathecal triamcinolone acetonide on spasticity in MS patients[J].CNS Neurosci Ther,2016,22(1):74-79.DOI:10.1111/cns.12474.
[12]WINGERCHUK D M,BANWELL B,BENNETT J L,et al.International consensus diagnostic criteria for neuromyelitis optica spectrum disorders[J].Neurology,2015,85(2):177-189.DOI:10.1212/WNL.0000000000001729.
[13]CAO H,PEYRODIE L,BOUDET S,et al.Expanded disability status scale(EDSS) estimation in multiple sclerosis from posturographic data[J].Gait Posture,2013,37(2):242-245.DOI:10.1016/j.gaitpost.2012.07.011.
[14]EHRENBORG C,GUSTAFSSON S,ARCHENHOLTZ B.Long-term effect in ADL after an interdisciplinary rehabilitation programme for WAD patients:a mixed-method study for deeper understanding of participants' programme experiences[J].Disabil Rehabil,2014,36(12):1006-1013.
DOI:10.3109/09638288.2013.825651.
[15]ASGARI N.Epidemiological,clinical and immunological aspects of neuromyelitis optica(NMO)[J].Dan Med J,2013,60(10):B4730.
[16]李昕頔,王化冰,周衡,等.脑脊液MOG抗体阳性的视神经脊髓炎谱系疾病患者的临床特征[J].中国神经免疫学和神经病学杂志,2017,24(4):249-255.
[17]董艳玲,李吕力,李瑶宣,等.鞘内注射甲基强的松龙治疗多发性硬化研究[J].天津医药,2012,40(1):12-14.
[18]MARCHESE D L.Poster 373 paradoxically increased rigidity after intrathecal baclofen injection in a patient with multiple sclerosis:acase report[J].PM R,2016,8(9S):S282.DOI:10.1016/j.pmrj.2016.07.300.
[19]顾亮亮,付国惠,张保朝,等.硫辛酸配合鞘内注射地塞米松对中枢神经系统脱髓鞘疾病患者神经功能的影响[J].中国实用神经疾病杂志,2018,21(10):1078-1082.
[20]张令霞.静脉应用联合鞘内注射药物治疗急性期视神经脊髓炎谱系疾病患者的疗效观察[D].石家庄:河北医科大学,2018.
[21]黄欣欣,丁婕,韩露,等.视神经脊髓炎谱系疾病患者血脑屏障通透性与肢体伤残的相关性分析[J].上海交通大学学报:医学版,2018,38(5):520-523.